The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN

Aberrant JAK2 tyrosine kinase signaling drives the development of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. However, JAK2 kinase inhibitors have failed to significantly reduce allele burden...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Mazzacurati, Lucia, Collins, Robert J., Pandey, Garima, Lambert-Showers, Que T., Amin, Narmin E., Zhang, Ling, Stubbs, Matthew C., Epling-Burnette, Pearlie K., Koblish, Holly K., Reuther, Gary W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6880903/
https://ncbi.nlm.nih.gov/pubmed/31725895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000260
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados